Listing J, Rau R, Müller B, Alten R, Gromnica-Ihle E, Hagemann D, Zink A
German Rheumatism Research Center, Berlin, Germany.
J Rheumatol. 2000 Sep;27(9):2100-9.
To evaluate the prognostic value of HLA-DRB1 antigens, rheumatoid factor (RF), and C-reactive protein (CRP) with the radiographic outcome of rheumatoid arthritis (RA).
In total, 139 patients with early RA (< 2 years) were followed up. At the end of 3 year treatment with disease modifying antirheumatic drugs (DMARD) HLA genotyping and external radiographic scoring were performed. The time up to the first development of erosive disease [Ratingen radiographic score (RS) > 0, > 5, > 10] was compared by methods of survival analysis.
At 4 years' disease duration, DRB104 or DRB101 positive patients had RS > 0 or > 10 (73% and 27%, respectively) significantly more frequently than DRB104 or DRB101 negative patients (37% and 7%, respectively). Nearly independently of the genetic predisposition, RF and elevated CRP at the start of DMARD treatment were predictive for erosive RA at 4 years. Elevated CRP (> or = 15 mg/l) increased the probability of erosive RA in DRB104 or DRB101 positive patients from 64.0% (in patients with CRP < 15 mg/l) to 83.9%, and in DRB1*04 and DRB1*01 negative patients from 18.8% to 70.1%. The corresponding figures for RF+ and RF- patients were 58.2% and 82.5% in HLA predisposed patients and 23.5% and 60.2% in those who were negative for DRB1*04 and DRB1*01. The probability of a RS > 10 was 40.9% for HLA predisposed patients with elevated CRP. In contrast, no case with RS > 10 was found in 43 patients who had neither of these 2 risk factors.
Our findings support that HLA predisposition plays an important role with regard to radiographic progression. However, this effect is modified by RF serum concentration and disease activity.
评估人类白细胞抗原-DRB1(HLA-DRB1)抗原、类风湿因子(RF)及C反应蛋白(CRP)对类风湿关节炎(RA)影像学结果的预后价值。
共纳入139例早期RA(病程<2年)患者进行随访。在使用改善病情抗风湿药物(DMARD)治疗3年结束时,进行HLA基因分型及影像学外部评分。采用生存分析方法比较出现侵蚀性疾病(伦琴影像学评分(RS)>0、>5、>10)的时间。
病程4年时,DRB104或DRB101阳性患者RS>0或>10(分别为73%和27%)的频率显著高于DRB104或DRB101阴性患者(分别为37%和7%)。几乎独立于遗传易感性,DMARD治疗开始时RF及CRP升高可预测4年后的侵蚀性RA。CRP升高(≥15mg/l)使DRB104或DRB101阳性患者发生侵蚀性RA的概率从64.0%(CRP<15mg/l患者)增至83.9%,DRB1*04和DRB1*01阴性患者从18.8%增至70.1%。HLA易感患者中RF阳性和阴性患者的相应数字分别为58.2%和82.5%,DRB1*04和DRB1*01阴性患者中分别为23.5%和60.2%。CRP升高的HLA易感患者RS>10的概率为40.9%。相比之下,43例无这两种危险因素的患者中未发现RS>10的病例。
我们的研究结果支持HLA易感性在影像学进展方面起重要作用。然而,这种作用会受到RF血清浓度和疾病活动度的影响。